THE EFFECT OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION AND PHARMACOTHERAPY ON SERUM PROTEIN S100B IN...

Area of Science:

• Neuroscience
• Psychiatry
• Biomarkers

Background:

• Major depressive disorder (MDD) is a prevalent condition with increasing treatment options.
• Identifying biomarkers to predict treatment response in MDD is crucial for personalized medicine.
• Transcranial magnetic stimulation (TMS) is an established, rapid treatment for MDD.

Purpose of the Study:

• To investigate changes in serum S100B concentrations following repetitive TMS (rTMS) and anti-depressant drug (AD) therapy in MDD patients.
• To evaluate S100B as a potential biomarker for treatment response in MDD.

Main Methods:

• A cohort study involving 48 participants: 16 healthy controls, 16 MDD patients treated with AD, and 16 drug-resistant MDD patients treated with rTMS plus AD.
• rTMS was applied to the left dorsolateral prefrontal cortex (DLPFC).
• Psychometric tests and serum S100B levels were measured at baseline and post-intervention.

Main Results:

• Serum S100B levels were significantly higher in both the AD and rTMS groups compared to healthy controls at baseline.
• A significant reduction in S100B levels was observed in the AD and rTMS groups from baseline to post-treatment.
• The study included 48 participants who completed the interventions.

Conclusions:

• rTMS of the DLPFC is an effective complementary treatment for treatment-resistant MDD.
• Elevated serum S100B concentrations may indicate a positive response to rTMS and AD therapy in MDD patients.
• S100B shows potential as a predictive biomarker for treatment efficacy in MDD.